Bristol-Myers Squibb (BMY) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus is a manageable bar, management guided toward the upper end of full-year ranges after Q1, and the growth portfolio has consistently beaten expectations; the biggest swing factor is whether the anticipated Eliquis inventory reversal and Opdivo normalization materialize as guided.

Heading into Q2 2026, BMY faces a consensus revenue bar of ~$11.73B and non-GAAP EPS of ~$1.60, both representing year-over-year growth versus Q2 2025 actuals of $12.27B and $1.47 (non-GAAP). Management explicitly flagged on the Q1 call that the ~$4.1B Eliquis inventory build from Q1 would reverse in Q2, creating a mechanical headwind to reported Eliquis revenue that is already embedded in consensus; the real question is whether underlying demand holds. Similarly, Opdivo’s Q1 decline to ~$2.1B was attributed to a wholesaler inventory drawdown, and management is monitoring normalization — a recovery toward the $2.46B Q2 consensus would be a meaningful positive signal. The growth portfolio (Camzyos, Breyanzi, Reblozyl, Cobenfy) has beaten expectations in each of the last four quarters, and management’s upper-end guidance tracking commentary after Q1 signals confidence in trajectory. The stock has outperformed both XBI (+12.6%) and the S&P 500 (+1.5%) since the April 30 print, gaining ~4% on an indexed basis, suggesting some beat expectation is already priced in but the multiple remains at a meaningful discount to large-cap pharma peers. The key wildcard is the iberdomide PDUFA date (August 17, 2026) — any pre-announcement or FDA communication ahead of earnings could move the stock materially, as approval would validate the CELMoD platform and open a significant new revenue stream in relapsed/refractory multiple myeloma.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — total revenue of ~$11.73B implies ~4.4% YoY decline vs. Q2 2025’s $12.27B (which included a strong Eliquis quarter), but the growth portfolio at ~$7.04B consensus is the real swing factor; non-GAAP EPS of ~$1.60 is achievable given Q1’s $1.58 beat and management’s upper-end guidance tracking.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 29, 2026. Q2 2026 Consensus vs. Guidance calculated against FY 2026 guidance midpoints where applicable.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Total Revenue & Non-GAAP EPS)

Pattern: BMY has beaten consensus on both Total Revenue and Non-GAAP EPS in each of the last four reported quarters, with revenue surprises ranging from +1.7% to +7.8% and EPS surprises consistently in the high single-digits to double-digits — a strong track record that sets a high bar for Q2 2026 but also suggests management guides conservatively.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: FY 2026 guidance was reaffirmed at Q1 earnings with management explicitly tracking toward the upper end of both revenue and EPS ranges — no formal revision since, but tone has shifted more confident with the Goldman Sachs conference commentary ruling out any ‘go slow’ posture on business development.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been essentially stable since the Q1 print — the ~5-day post-earnings baseline and current consensus are nearly identical, suggesting the market fully digested Q1 guidance and is not pricing in incremental upside or downside; the gap between FY 2026 revenue consensus (~$47.45B) and the top of guidance ($47.0B) implies the street is already modeling a modest beat.

Estimates have been remarkably stable since the Q1 print — virtually no revision in either direction for Q2 or FY 2026, suggesting the street has high conviction in management’s guidance. The notable gap is FY 2026 non-GAAP EPS consensus ($6.34) sitting ~5.5% below the guidance midpoint ($6.70), which likely reflects analyst conservatism on R&D spend and product mix; if management reaffirms upper-end tracking on the Q2 call, this gap represents meaningful upside to EPS estimates.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: BMY has outperformed both the biotech sector (XBI) and the S&P 500 since the Q1 2026 earnings print, gaining ~4% on an indexed basis vs. XBI +12.6% and SPY +1.5% — the stock’s relative underperformance vs. XBI reflects sector-wide biotech momentum rather than BMY-specific weakness, while its absolute gain suggests the Q1 beat and upper-end guidance tracking have been partially priced in.

BMY vs. XBI (Biotech ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (April 30, 2026). Source: Yahoo Finance.

BMY opened Q2 at $60.59 on April 30 (earnings day) and closed at $63.10 on July 29, 2026, a gain of approximately +4.1% on an absolute basis. The XBI biotech ETF gained +12.6% over the same period, reflecting broad sector tailwinds from pipeline catalysts across large-cap pharma. The S&P 500 gained +1.5%. BMY’s relative underperformance vs. XBI is consistent with its defensive, large-cap pharma profile — the stock does not participate fully in risk-on biotech rallies. Key events during the period include the Hengrui collaboration announcement (May 12), the Goldman Sachs Healthcare Conference (late May), and the June 18 announcement of the Q2 earnings date. The stock has been range-bound in the low-to-mid $60s since mid-June, suggesting the market is waiting for the Q2 print and the iberdomide PDUFA (August 17) before re-rating.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Hengrui Pharma collaboration (May 12), which represents one of the largest early-stage BD deals BMS has executed and validates management’s more aggressive BD posture; the iberdomide PDUFA (August 17) is the single biggest near-term binary catalyst.

• May 12, 2026 — Hengrui Pharma Strategic Collaboration Announced. BMS announced a major collaboration covering a portfolio of early-stage programs across oncology, hematology, and immunology. Structure includes four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five jointly discovered programs. BMS obtains exclusive worldwide rights to Hengrui-originated assets outside mainland China/HK/Macau. Deal subject to antitrust review, expected to close Q3 2026. Implication: Validates management’s ‘right to win’ BD strategy and signals confidence in balance sheet capacity; one of the largest early-stage collaboration structures BMS has executed.
• August 17, 2026 — Iberdomide PDUFA Date (Relapsed/Refractory Multiple Myeloma). FDA decision expected for iberdomide in R/R MM. Management has highlighted MRD negativity rates significantly higher than historical standards as a potential accelerated approval pathway. Implication: Approval would be a major catalyst validating the CELMoD platform and opening a new revenue stream; any pre-announcement or FDA communication ahead of the July 30 earnings call could move the stock.
• May 2026 (ASCO) — Multiple Pipeline Data Readouts. Iza-bren (EGFR/HER3 ADC) delivered positive Phase III interim data in triple-negative breast cancer and esophageal squamous cell carcinoma. Golcadomide, mezigdomide, and iberdomide data also presented. PRMT5 inhibitor (navlimetostat) RAS inhibitor combination data described as ‘derisking’ the combination hypothesis. Implication: Broad pipeline validation across multiple platforms; CMO designated navlimetostat a ‘very high priority’ asset.
• Late May 2026 — Goldman Sachs 47th Annual Global Healthcare Conference. Management explicitly ruled out any ‘go slow’ posture on BD, stated activity is not contingent on Phase 3 readout outcomes. CMO outlined 12-13 total Cobenfy pivotal studies spanning multiple indications. PPF readout for admilparant now guided to early 2027 (vs. H2 2026 prior), with combined IPF/PPF regulatory filing strategy now being considered. Implication: More aggressive BD tone and expanded Cobenfy program scope are positive signals; PPF timeline slip is minor given combined filing strategy.
• June 17, 2026 — Quarterly Dividend Declared. Board declared $0.63/share quarterly dividend, payable August 3, 2026 to shareholders of record July 2, 2026. Implication: Reaffirms capital return commitment and strong cash flow generation.
• June 18, 2026 — Q2 2026 Earnings Date Announced. BMS confirmed July 30, 2026 before market open, with conference call at 8:15 AM ET.
• May 8, 2026 — Annual Meeting: Shareholders Back Management. Shareholders approved key management proposals and rejected an independent board chair mandate. Implication: Governance stability; no activist disruption risk heading into a critical pipeline readout year.
• Q2 2026 — Camzyos Competition (Aficamten/Myqorzo Launch). Aficamten commercially launched but still operationalizing its REMS program. Management reports HCPs see little differentiation; ~25,000 U.S. patients on Camzyos with established REMS infrastructure and simpler dosing (90% on 5mg starting dose). Implication: Camzyos Q2 revenue ($357M consensus) will be the first full quarter with a commercial competitor — any share loss or pricing pressure would be a negative read-through.
• Ongoing — Cobenfy ADEPT Program (Alzheimer’s Psychosis). ADEPT-1, 2, and 4 readouts expected by end of 2026. ADEPT-2 continuing with additional enrollment after DMC recommendation. ADEPT-4 uses biomarker-selected population. ADEPT-5 added, bringing total to four shots on goal. Implication: Two positive studies needed for filing; any interim signal or DMC update could be a major catalyst.

7. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for BMY’s Q2 2026 print — JNJ’s Q2 2026 results (reported July 15) confirm robust multiple myeloma market growth and strong HCM-adjacent cardiovascular demand, AZN’s Q2 2026 results (reported July 27) validate the oncology ADC and checkpoint inhibitor market backdrop, and GILD’s Q1 2026 commentary (May 7) highlights intensifying CAR-T competition in multiple myeloma that BMY must navigate with Abecma and Breyanzi.

JNJ Q2 2026 (Reported July 15, 2026) — Most Relevant Read-Through

Relevance: HIGH. JNJ is BMY’s most direct peer in multiple myeloma, immunology, and cardiovascular. JNJ reported Q2 2026 on July 15 — the most timely read-through available for BMY’s Q2 print.

• Multiple Myeloma Market Remains Robust. Darzalex delivered $4B+ in Q2 2026, growing ~18% operationally with 5 points of share gain across all lines of therapy and nearly 11 points in frontline. Carvykti (CAR-T) grew 47.7%, Tecvayli grew 56.1%, and Talvey grew 62.6%. BMY Read-Through: The overall MM market is growing strongly, which is a positive backdrop for BMY’s Breyanzi (CAR-T, $430M Q2 consensus) and Reblozyl ($661M Q2 consensus). However, JNJ’s aggressive expansion into earlier lines of therapy with bispecifics and CAR-T creates competitive pressure on Abecma and the broader BMS hematology franchise.
• Immunology: IL-23 Dominance and Oral Systemic Competition. Tremfya grew 71% to $2B in Q2 2026, leading in both Crohn’s and UC. I-coded (oral IL-23 for psoriasis) launched with strong early momentum — 11,000 patients, 6,000 prescribers, >50% commercial coverage within 90 days. BMY Read-Through: Sotyktu (TYK2 inhibitor for psoriasis) faces a new oral competitor in I-coded. The rapid uptake of I-coded in psoriasis could pressure Sotyktu’s new patient share, particularly given I-coded’s positioning as a ‘first-choice systemic’ for patients cycling off topicals.
• Milvexian (Factor XIa) — Shared Pipeline Asset. JNJ confirmed Milvexian event-driven studies are fully recruited; readout could be end of 2026 or early 2027. JNJ cited ~40% of AFib patients eligible for anticoagulants not receiving them due to bleeding concerns, and estimated 18M Americans should be on anticoagulants vs. 8M currently. BMY Read-Through: BMY co-develops milvexian with JNJ. JNJ’s confidence in the dose/schedule for AFib and the large commercial opportunity is directly positive for BMY’s pipeline valuation. Any JNJ commentary on trial progress is a direct read-through.
• Biosimilar Impact on Stelara — Lifecycle Management Warning. Stelara declined 55.7% in Q2 2026, now only 4% of JNJ’s innovative medicine business. BMY Read-Through: Validates the urgency of BMY’s growth portfolio strategy to offset legacy LOE headwinds (Revlimid, Pomalyst). The pace of biosimilar erosion at JNJ is a cautionary benchmark.

AZN Q2 2026 (Reported July 27, 2026) — Oncology Backdrop

Relevance: MEDIUM-HIGH. AZN reported Q2 2026 on July 27 — two days before BMY’s earnings. AZN’s oncology commentary is the most current read-through for the checkpoint inhibitor and ADC market.

• Oncology Market Growing Strongly. AZN oncology revenues grew 15% in H1 2026 to $14.1B, with 18% U.S. growth. Enhertu grew 31% in Q2. Imfinzi/Imjudo grew 25% in aggregate. BMY Read-Through: Broad oncology market growth is a positive backdrop for Opdivo ($2.46B Q2 consensus). AZN’s strong checkpoint inhibitor performance suggests the market is not contracting, supporting BMY’s Opdivo recovery thesis from Q1’s inventory-driven decline.
• ADC Competition Intensifying. AZN announced positive Phase 3 results for Sony VE (Claudin 18.2 ADC) in gastric cancer, estimated peak revenue $3-5B. AZN’s bispecifics ambition is to ‘replace the current generation of checkpoint inhibitors.’ BMY Read-Through: Validates the strategic importance of BMY’s iza-bren (EGFR/HER3 ADC) and pumitamig (BNT327, PD-L1/VEGF bispecific) programs. The ADC/bispecific wave is real and accelerating — BMY’s pipeline positioning in these modalities is increasingly important for long-term valuation.
• Wainua (Amyloid Cardiomyopathy) Trial Miss. AZN’s Cardio Transform trial for Wainua in ATTR-CM did not meet its primary endpoint. BMY Read-Through: Neutral for BMY directly, but reinforces the difficulty of cardiovascular outcomes trials. Camzyos’ established efficacy in oHCM is a competitive moat.
• Generic Pressure on Farxiga — 90% Revenue Decline. Farxiga declined 90% in Q2 due to U.S. generic entry. BMY Read-Through: Stark reminder of LOE risk; BMY’s Revlimid and Pomalyst are in various stages of generic erosion. The pace of AZN’s Farxiga decline is a benchmark for how quickly revenues can collapse post-LOE.

GILD Q1 2026 (Reported May 7, 2026) — CAR-T & Hematology Competition

Relevance: MEDIUM. GILD reported Q1 2026 on May 7. Key read-through is the CAR-T competitive landscape in multiple myeloma and the broader cell therapy market.

• Anito-cel (BCMAxCAR-T) — Direct Abecma Competitor. Gilead’s acquisition of Arcellx closed April 28. Anito-cel PDUFA date is December 2026, with revenue expected to begin early 2027. Gilead highlighted ‘no delayed or non-ICANS neurotoxicities and enterocolitis’ as a differentiated safety profile. Phase III iMMagine-3 (2nd-4th line) enrollment completed ahead of schedule. BMY Read-Through: Anito-cel is a direct threat to Abecma (BCMA-directed CAR-T). Gilead’s aggressive positioning and ‘best-in-disease’ framing, combined with Kite’s manufacturing capabilities, could accelerate share loss for Abecma in 2027. BMY’s Breyanzi (CD19 CAR-T, different target) is less directly impacted.
• Cell Therapy Sales Down 12% YoY. Gilead’s Q1 2026 cell therapy sales were $407M, down 12% YoY, attributed to ‘ongoing in and out-of-class competition.’ BMY Read-Through: Gilead’s cell therapy weakness is partly a Yescarta-specific dynamic (DLBCL competition), but the broader competitive intensity in cell therapy is a relevant backdrop for BMY’s Breyanzi ($430M Q2 consensus). Breyanzi’s 53% Q1 growth suggests it is taking share from Yescarta, which is a positive signal.
• Autoimmune Expansion — Gamgertamig (BCMAxCD3 T-cell Engager). Gilead’s pending acquisition of Ouro Medicines adds gamgertamig for B-cell-driven autoimmune diseases. Phase III registrational trials targeted as early as 2027. BMY Read-Through: Validates the autoimmune immune-reset strategy that BMY is pursuing with arlo-cel (autologous CAR-T in lupus/scleroderma) and its allogeneic CAR-T program. The competitive landscape in autoimmune cell therapy is intensifying.
• Trodelvy (ADC) Growing 37% YoY. Trodelvy Q1 2026 sales up 37% YoY; first-line TNBC regulatory decision expected H2 2026. BMY Read-Through: Validates the ADC market opportunity. BMY’s iza-bren (EGFR/HER3 ADC) positive Phase III interim data in TNBC at ASCO positions it as a potential competitor to Trodelvy in future lines.

PFE Q1 2026 (Reported May 5, 2026) — Eliquis & Oncology Backdrop

Relevance: MEDIUM. PFE reported Q1 2026 on May 5. Key read-through is Eliquis (co-promoted with BMS) and the broader oncology competitive landscape.

• Eliquis Confirmed as ‘Solid Contributor’ in Q1 2026. Pfizer cited Eliquis as a primary driver of Q1 results alongside Padcev, Nurtec, Lorbrena, and Vyndaqel. Pfizer reaffirmed FY 2026 guidance with mid-70s adjusted gross margins. BMY Read-Through: Pfizer’s Eliquis commentary is directly relevant — both companies co-promote the drug. Pfizer’s confirmation of strong demand supports BMY’s Q2 Eliquis consensus of $3.97B (which already embeds the Q1 inventory reversal). No negative demand signals from the Pfizer call.
• Multiple Myeloma — Elrexfio Phase III Positive (MagnetisMM-5). Pfizer’s Elrexfio significantly improved PFS for double-class exposed R/R MM patients. BMY Read-Through: Adds another competitor in the R/R MM space where BMY competes with Abecma and CELMoDs. The MM treatment landscape is becoming increasingly crowded with bispecifics and CAR-Ts.
• Oncology ADC Pipeline Advancing. Pfizer’s Padcev (EV) data showed ~50% reduction in recurrence/death risk in muscle-invasive bladder cancer. Seagen products grew 20% YoY. BMY Read-Through: Validates the ADC modality’s commercial potential. BMY’s iza-bren in bladder cancer (Phase 3 ongoing) will compete in this space.
• Pfizer FY 2026 Guidance Reaffirmed ($59.5–$62.5B Revenue). Pfizer’s reaffirmation of guidance and cost discipline commentary is consistent with the broader large-cap pharma theme of managing through LOE headwinds while investing in growth. BMY Read-Through: Sector-level read-through that large-cap pharma guidance is holding — positive for BMY’s own guidance reaffirmation credibility.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells since the Q1 2026 earnings print — all transactions since April 30 are routine compensation-related (deferred share unit grants, RSU vesting, option exercises, and tax withholding dispositions). The absence of any open-market purchases or discretionary sales is neutral; insiders are neither signaling conviction through buying nor concern through selling.

Source: SEC Form 4 Filings Database. Period covered: April 30, 2026 – July 29, 2026. Only Form 4 filings with transaction codes P (open-market purchase) or S (open-market sale) would constitute discretionary insider activity. No such transactions were identified in the period. All transactions above are compensation-related (DSU grants, RSU/MSU vesting, option exercises, and tax withholding dispositions).

Appendix: Key Upcoming Catalysts